News
MyChesCo on MSN2h
Windtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study Results
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has reported encouraging interim results from its ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback